Gain Therapeutics appoints Jeanette Weidner as vice president, finance

Gain Therapeutics, Inc. (NASDAQ:GANX) announced Wednesday the appointment of Jeanette Weidner as vice president, finance, effective the same day. According to a press release statement based on a recent SEC filing, Ms. Weidner will also serve as the company’s principal financial officer and principal accounting officer.

Ms. Weidner, age 44, brings 18 years of accounting and finance experience, including over a decade in the life sciences sector. Before joining Gain Therapeutics, she was a financial consultant for Senseonics Holdings Inc. (NASDAQ:SENS) from March 2025 to October 2026, focusing on financial reporting and operational accounting. She previously served as vice president, finance, at OncoC4, Inc., a private late clinical-stage biopharmaceutical company, from March 2021 to January 2025.

Ms. Weidner holds an undergraduate degree from Salisbury University and completed accounting studies at the University of Maryland Global Campus. She maintains an active CPA license.

Under the terms of her employment agreement, Ms. Weidner will receive an annual base salary of $275,000 and is eligible for an annual incentive cash bonus initially targeted at 35% of her base salary, subject to board discretion. She will also receive an option to purchase up to 130,000 shares of Gain Therapeutics common stock at the fair market value on the grant date, vesting over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments. InvestingPro subscribers can access 6 additional exclusive tips about GANX, along with comprehensive financial health scores and detailed valuation metrics.

Ms. Weidner is eligible for additional equity incentive grants as determined by the board and may participate in employee benefit plans available to similarly situated executives.

In the event of termination without cause, for good reason, or due to death or disability after three months of employment, Ms. Weidner is eligible for six months of base salary as severance and continuation of health coverage for six months. If such termination occurs in connection with a change of control, severance increases to twelve months of base salary, health coverage for twelve months, pro-rated and target annual bonuses, and accelerated vesting of unvested stock awards.

The company stated there are no related party transactions or family relationships involving Ms. Weidner requiring disclosure.

In other recent news, Gain Therapeutics has presented long-term data from its Phase 1b study of rexaceract (GT-02287) for Parkinson’s disease. The data was shared at the International Congress of Parkinson’s Disease and Movement Disorders, showing that 12 out of 13 patients completed the 12-month administration, with one more participant expected to finish dosing by November 2026. Additionally, Gain Therapeutics announced the resignation of its Senior Vice President of Finance, Gianluca Fuggetta, effective September 30, as he pursues other opportunities. Gene Mack, the current President and CEO, has been appointed as the interim Chief Financial Officer while the company searches for a permanent replacement.

Moreover, Gain Therapeutics received FDA authorization for its Investigational New Drug application for GT-02287, which will enable the commencement of a Phase 2 clinical assessment in the U.S. H.C. Wainwright reiterated a Buy rating and set a $8.00 price target on Gain Therapeutics shares, following this development. BTIG also maintained a Buy rating with a $5.00 price target, reflecting confidence in the company’s recent trial data. These developments highlight the ongoing progress and strategic changes within Gain Therapeutics.